Abstract:
Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.
Abstract:
Dimethoxyphenol-based monomers containing polymerizable functional groups such as [meth]acrylate groups are useful for the preparation of polymers, wherein one or more dimethoxyphenyl moieties are part of side chains pendant to the backbones of the polymers. The polymers thereby obtained may have different, improved properties, such as higher glass transition temperatures, thermal stability and solvent resistance, as compared to polymers based on other types of lignin-derived monomers.
Abstract:
The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings: wherein at least one of R1 and R2 is a straight or branched chain C1-C12 alkoxy radical, preferably C1-C8, more preferably C1-C4, and most preferably methoxy, and any non-alkoxy radical R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C24 alkyl radical, preferably C12-C24, more preferably C20; wherein A and B are the same or different and are selected from the group consisting of oxygen, amino and sulfur; R1 and R3 are the same or different and are selected from the group consisting of C1-C30 alkyl, C2-C30 alkylene, C2-C30 alkyne, C3-C8 cycloalkyl, C1-C30 substituted alkylene, C2-C30 substituted alkyne, aryl, substituted aryl, heteroaryl, heterocycloalkyl, substituted heteroaryl and substituted heterocycloalkyl; R2 is selected from the group consisting of C1-C30 alkyl, C2-C30 alkylene, C2-C30 alkyne, C3-C8 cycloalkyl, C1-C30 substituted alkyl, C3-C8 substituted cycloalkyl, C1-C30 substituted alkylene, C2-C30 substituted alkyne; R4, R5, R6 and R7 are the same or different and are selected from the group consisting of C1-C30 alkoxy straight chain on branched and a, b, c and d are each either 0 or 1, and a, b, c and d add up to 1, 2, 3, or 4.
Abstract:
This invention describes the use of S-(+)-abscisic acid (ABA) or its salts in combination with gibberellin biosynthesis inhibitors to improve the performance of gibberellin synthesis inhibitors, and to increase water conservation in plants such as turfgrass.
Abstract:
Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds have the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(e): ##STR2## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.
Abstract:
The invention relates to a process for preparing monofunctional, bifunctional or polyfunctional aromatic olefins of the formula (I) ##STR1## by reaction of haloaromatics of the formula (II) ##STR2## with olefins of the formula (III) ##STR3## , wherein a palladium compound of the formula (IV) ##STR4## is used as the catalyst.
Abstract:
This invention relates to a compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof wherein X is oxygen, sulfur, --CH.dbd.CH--, or --CH.dbd.N--; wherein R.sup.1 is --CO.sub.2 R.sup.2 or tetrazole; wherein R.sup.2 is hydrogen, alkyl of 1 to 6 carbons or a pharmaceutically acceptable cation; wherein R is an alkyl of from 1 to 20 carbons, --(CH.sub.2).sub.p CF.sub.3 or --(CH.sub.2).sub.q R.sup.3 wherein R.sup.3 is alkoxy, phenoxy or alkoxy substituted phenoxy wherein the alkoxy group has from 1 to 8 carbons; wherein p and q are integers from 0 to 20; wherein n is 0 or 1; and wherein m is 0, 1, 2, or 3.
Abstract:
A method for selective dehydrogenation of a compound, comprising contacting a compound of the formula ##STR1## wherein each R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from the group consisting of H, (C.sub.1 -C.sub.20) alkyl, (C.sub.3 -C.sub.20) cycloalkyl, (C.sub.6 -C.sub.20) aryl, (C.sub.7 -C.sub.20) alkylaryl, (C.sub.7 -C.sub.20) aralkyl groups, as well as substituted (C.sub.1 -C.sub.20) alkyl, (C.sub.3 -C.sub.20) cycloalkyl, (C.sub.6 -C.sub.20) aryl, (C.sub.7 -C.sub.20) aralkyl and (C.sub.7 -C.sub.20) arylalkyl moieties, optionally further substituted with --OR, wherein R is R.sup.1, R.sup.2, R.sup.3 or R.sup.4 ; and wherein R.sup.1 and R.sup.2 or R.sup.3 and R.sup.4 may be joined as part of a ring structure, at a dehydrogenation temperature in the presence of a catalyst comprising about 0.01 wt %-19.9 wt % Pd and about 0.01 wt %-19.9 wt % Cu on a carbon support, wherein the total amount of (Pd+Cu) on the support is about 0.02 wt % to 20 wt %, the weight ratio of Pd:Cu is about 1:1 to 10:1, and the carbon support has a surface area of at least about 100 m.sup.2 /g and is essentially free of reactive sulfur.A selective dehydrogenation catalyst having the composition described supra is disclosed as is a method of preparing the same. This catalyst is highly selective for dehydrogenating a variety of substrates while minimizing the formation of unwanted hydrogenolysis by-products.
Abstract:
An alkanoic acid compound is disclosed of formula: ##STR1## and certain of its physiologically acceptable salts and esters. The alkanoic acid compound and its salts and esters have an unexpectedly greater anti-inflammatory activity than representative members of a broad class of compounds, phenyl alkane derivatives, known to have therapeutic properties. The alkanoic acid compound also has unexpectedly high antipyretic and analgesic activity. The compounds may be formulated in conventional manner as pharmaceutical compositions.The compound may be prepared from 2-[4-(1-hydroxy-2-dimethylethyl)phenyl] propionic acid directly by dehydration or via an ester by dehydration in the presence of an alkanol followed by hydrolysis.